Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3–5cm: A propensity score matching study

Li, Minpeng; He, Jun; Pan, Meng; Yu, Yuan; Zhuang, Ping; Xu, Baojun; Zhu, Jinmin

doi:10.1016/j.dld.2016.06.007

Cited by 19 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study comparing the efficacy of RFA alone and the combination of RFA and iodine 125 seeds implantation in the treatment of early HCC has demonstrated that the RFA-Iodine 125 group had longer survival than the group treated with RFA alone [16]. Additional studies have compared the effects of TACE-Iodine 125 seeds implantation with those of TACE alone in the treatment of HCC based on BCLC stage or tumor size; the results indicated better outcomes in patients treated with the combination therapy [18,23,24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Transarterial Chemoembolization Combined with Iodine 125 Seeds Versus Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Early and Intermediate Hepatocellular Carcinoma

Chen

Kan

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background To compare the efficacy of the combination of transarterial chemoembolization (TACE) and iodine 125 seeds implantation (TACE-Iodine 125) with the combination of TACE and radiofrequency ablation (RFA) in the treatment of patients with early and intermediate hepatocellular carcinoma (HCC). Methods The study included 134 patients diagnosed with early and intermediate HCC from January 1, 2014, to May 31, 2018. Among them, 47 patients were treated with TACE-Iodine 125, and 87 with TACE-RFA and the efficacy of both treatments was analyzed. To reduced selective bias, propensity score matching (PSM) was used to compare the outcomes of the treatments. Results In the absence of PSM, the median overall survival (OS) and progression-free survival (PFS) of the TACE-RFA group were slightly longer than those of the TACE-Iodine 125 group (OS: 42 months vs. 37 months; PFS: 18 months vs. 15 months). However, there was no significant difference in median OS, PFS, and the objective response rate (ORR) between the two groups (P>0.05). After adjusted for age, gender, liver resection, Child-Pugh class, Barcelona Clinic Liver Cancer (BCLC) stage and Alpha-fetoprotein (AFP), TACE-Iodine 125 treatment was not associated with a significant increasing in risk of death (HR: 0.725; 95%CI: 0.423,1.241, P=0.241) and recurrence (HR: 1.008; 95%CI: 0.666,1.526, P=0.969). After PSM, 47 patient pairs were generated, and there was no significant difference in median OS and PFS between the two groups. Conclusions The combination of TACE and iodine 125 seeds implantation may represent an effective treatment for patients with early and intermediate HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Typically, in the treatment of HCC, the implantation of iodine 125 seeds is combined with other modalities, such as RFA or surgery [16,17]. It has been demonstrated that at different stages of HCC, the combination of TACE with iodine 125 seeds implantation provides longer patient survival than TACE alone [18,19].…”

Section: Introductionmentioning

confidence: 99%

Transarterial Chemoembolization Combined with Iodine 125 Seeds Versus Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Early and Intermediate Hepatocellular Carcinoma

Chen

Kan

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…2). Two-year survival rate was reported in 2 studies, 22,24 TACE plus iodine-125 seed implantation (248 (59.0%) patients) has a higher two-year survival rate compared with TACE alone (172 (41.0%) patients) (OR: 4.72, 95% CI: 2.63-8.47; P < 0.001) (Fig. 3).…”

Section: Quality Assessmentmentioning

confidence: 94%

“…Finally, 9 studies were included for analysis, 16,[22][23][24][25][26][27][28][29] including 2 randomized controlled trials (RCTs), 16,28 and 7 non-RCTs. [22][23][24][25][26][27]29 These studies were published from 2008 to 2017 and all of them investigated the therapy of TACE plus iodine-125 seed implantation. A total of 894 patients were included in these studies.…”

Section: Literature Search and Description Of The Studiesmentioning

confidence: 99%

“…The heterogeneity was low among the trials. Seven studies, 16,[22][23][24][25]27,29 reported 1-year survival. TACE plus iodine-125 seed implantation (427 (54.6%) patients) was associated with a higher one-year survival rate compared with TACE alone (355 (45.4%) patients) (odds ratio (OR): 4.47, 95% confidence intervals (CI): 2.97-6.73; P < 0.001).…”

Section: Quality Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis

Zhu

Wang

Yuan

et al. 2018

HPB

View full text Add to dashboard Cite

show abstract

Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation‐based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection

Yang

Zhu

Zhao

et al. 2017

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3–5cm: A propensity score matching study

Cited by 19 publications

References 34 publications

Transarterial Chemoembolization Combined with Iodine 125 Seeds Versus Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Early and Intermediate Hepatocellular Carcinoma

Transarterial Chemoembolization Combined with Iodine 125 Seeds Versus Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Early and Intermediate Hepatocellular Carcinoma

Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis

Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation‐based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection

Contact Info

Product

Resources

About